The HealthCare atHome (HCAH) a joint-venture between the Burman family (promoters of Dabur) and founders of HealthCare atHome, UK, enters into disease management services with the acquisition of Health Impetus Pvt. Ltd., a disease management company involved in providing innovative solutions for the pharma companies to engage patients and doctors. With this new portfolio of services HCAH claims to be a one stop solution for every segment of the healthcare delivery channel especially pharma sector.

The acquisition has marked HCAH’s entry into disease management services thereby becoming an integrated care management company which is focused on making a real difference to patient care, outcomes and cost of treatment. HCAH will provide an array of services which include: Disease awareness and diagnostics, patient support and awareness programs, management of diseases through compliance programs, drug delivery and administration, Data analysis and outcome standardization.

The integration besides offering a bouquet of services for disease management will also roll out a range of patient care services like EMI schemes for chronic ailments like cancer, diabetes, hepatitis B etc which will help patients to continue the treatment and meet the high cost of medications.

Vivek Srivastava, co-founder and chief executive officer at HCAH, says, “At HealthCare atHome India, it is our endeavor to put in place a holistic system of quality health-care which is easily accessible at the patient’s doorstep.  With this acquisition, HCAH has increased its bouquet of services to pharma companies. HCAH brings superior clinical skills and Direct to Patient pharmacy delivery skills thus becoming a One Stop Solution to the pharma companies in the patient journey.”

Speaking on the acquisition, Pankaj Sindhu, Founder Health Impetus, added, “This is the beginning of an exciting chapter for HIPL and as it becomes a part of the HCAH family. HCAH has unmatched expertise in providing technology driven home healthcare services to patients across the country.  This was a natural match for both the companies and I am confident that the synergies between both the companies will help in evolving superior quality solutions for our clients in the pharma sector and patients”

The pharma sector is undergoing rapid change because of new regulations which are coming in and more tightening of government regulations on doctor engagement programs. This implies more marketing money being spent on patient engagement programs to create differentiation in their products and engaging the patients more with their brand. HCAH brings to the table 20 years of learning of managing such programmes across almost all global pharma companies in UK, Europe and Australia through the legacy of the founders of HealthCare atHome UK (HaH).

HCAH also provides a multitude of clinical homecare services which include specialty services like Chemotherapy at Home, Home ICU, post -operation recovery care, palliative care to terminally ill patients.  Besides these, it also provides day to day healthcare services like elderly care, bed sore care, injection administration etc. Most of the services provided by HCAH are cheaper than those provided by a hospital and that too right at the comfort of the patient’s home.

The combined entity (HCAH+ HIPL) now has managed 3 lac + patients across 30 cities in India.